FDA 批准 Ionis 反义寡核苷酸药物 Zanvastro 用于 Alexander 病
FDA nod for rare neurology drug
FDA 已批准 Ionis Pharmaceuticals 的 Zanvastro(zilganersen)用于罕见进行性神经疾病 Alexander 病,原文称其为该病首个改善病程的药物。
- News in Brief
- Published: 12 October 2026
Nature Biotechnology volume 44, page 1593 (2026) Cite this article
The US Food and Drug Administration has given the green light to Ionis Pharmaceuticals’ Zanvastro (zilganersen), the first disease-modifying drug for a rare, progressive and often fatal neurological condition known as Alexander disease. Zanvastro is an antisense oligonucleotide that targets RNA encoding glial fibrillary acidic protein (GFAP), which is overexpressed in astrocyte cells in Alexander disease because of mutations in the GFAP gene.
Zanvastro works by reducing GFAP overproduction in astrocytes. If there is too much GFAP, it forms clumps that cause astrocytes to malfunction and disrupt myelination in nerve-cell axons. People with Alexander disease have impaired motor function, seizures, intellectual disability and developmental delays; it affects about one person out of every 1–3 million.
This is a preview of subscription content, access via your institution
Access options
Access through your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
27,99 € / 30 days
cancel any time
Subscription info for Chinese customers
We have a dedicated website for our Chinese customers. Please go to naturechina.com to subscribe to this journal.
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
39,95 €
Prices may be subject to local taxes which are calculated during checkout
Additional access options:
About this article
Cite this article
FDA nod for rare neurology drug. Nat Biotechnol 44, 1593 (2026). https://doi.org/10.1038/s41587-026-03349-0
Published: 12 October 2026
Version of record: 12 October 2026
Issue date: October 2026
DOI: https://doi.org/10.1038/s41587-026-03349-0
来源:Nature Biotechnology · nature.com